CART-19 cells

BIOLOGICAL5 trials

Sponsors

University of Pennsylvania, Henan Cancer Hospital, Fujian Medical University, The Affiliated Hospital of the Chinese Academy of Military Medical Sciences

Conditions

B-cell Acute Lymphoblastic LeukemiaLeukemia, Lymphocytic, AcuteMultiple MyelomaRelapsed or Refractory B-cell LymphomaRelapsed/Refractory B-cell ALL

Phase 1

The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).

Henan Cancer HospitalB-cell Acute Lymphoblastic Leukemia

Start: 2016-07-18End: 2019-12-31Target: 20Updated: 2017-12-29

CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia （ALL）

The Affiliated Hospital of the Chinese Academy of Military Medical SciencesLeukemia, Lymphocytic, Acute

Start: 2018-03-01End: 2020-03-01Target: 10Updated: 2018-06-04

Phase 2

CART-19 Post-ASCT for Multiple Myeloma

TerminatedNCT02794246

University of PennsylvaniaMultiple Myeloma

Start: 2016-06-30End: 2019-05-31Updated: 2023-06-22

CART-19 Cells for R/R B-cell Lymphoma

Fujian Medical UniversityRelapsed or Refractory B-cell Lymphoma

Start: 2016-01-01End: 2020-12-31Target: 20Updated: 2018-01-05

CART-19 Cells For R/R B-ALL

Fujian Medical UniversityRelapsed/Refractory B-cell ALL

Start: 2016-01-31End: 2019-12-31Target: 20Updated: 2018-01-05

Related Papers

Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy.

2021-02-156 citations

Superior Outcomes in Relapsed/Refractory Childhood B-ALL Than Adult Patients with CD19 CAR-T Cell Therapy: A Single-Center Pilot Prospective Study of 23 Patients

Blood2019-11-131 citations

Repeat Infusion of CD19-Specific Chimeric Antigen Receptor T-Cell Could Improve the Efficacy with Consistent Safety in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood2018-11-291 citations

Treatment of relapsed/refractory (R/R) B-cell malignancies by chimeric antigen receptor T cells cultured from 50-100 mL peripheral blood in 7-10 days.

Journal of Clinical Oncology2018-05-20